1 Clinicaltrials.gov, “Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above”. Available at: https://clinicaltrials.gov/study/NCT04886596 - last accessed: September 2024 2 National Institute of Allergy and Infectious Diseases, Respirat...
Arexvy疫苗于2023年获得美国FDA批准,用于预防60岁及以上人群的RSV相关下呼吸道疾病。 这项研究为制定RSV疫苗的接种策略提供了重要依据,表明单剂接种可能在多个季节中提供持续保护,减少老年人群的疾病负担。
图片来源:《Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults》-NEJM 02 RSV疫苗的商业未来 目前市面上已上市的两款疫苗均为重组蛋白疫苗,也就是疫苗中并没有“真病毒”,而是将RSV病毒上的“F”蛋白作为抗原,更准确的说,是与人体细胞融合之前的“F”蛋白。这是一种非常巧妙的设计,...
“We expect this to be a tremendously important vaccine both for public health and for the company.” In briefing documents provided in advance of a March 2023 adcomm recommendation, GSK presented efficacy numbers for its candidate, with a vaccine efficacy of 82.6% in preventing RSV-induced ...
Safety and efficacy of mRNA-1345, an mRNA-based vaccine against respiratory syncytial virus, in adults 60 years and older (oral presentation). Presented at RSSVW'23, 22-24 February 2023, Lisbon, Portugal. https://s29.q4cdn.com/435878511/files/doc_downloads/program_detail/2023/09/RSV-09-...
GSK plc (LSE/NYSE: GSK) today announced positive preliminary results from its phase III trial [NCT05590403] evaluating the immune response and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50 to 5...
Efficacy against severe RSV-LRTD, defined as an RSV-associated LRTD episode preventing normal, everyday activities, was 94.1% (95% CI, 62.4–99.9, 1 of 12,466 vs 17 of 12,494). The vaccine was generally well tolerated with an acceptable safety profile....
The results show that one dose of the vaccine is efficacious against RSV-LRTD and severe LRTD over two full RSV seasons. A similar pattern of vaccine efficacy over two seasons was also observed in adults with underlying comorbidities ...
2024年5月1日,葛兰素史克发布一季度财报,营业收入73.67亿英镑,同比增长10%,去除新冠产品影响,同比增长13%。 2024年Q1疫苗业务呼吸道RSV疫苗Arexvy增长22%,带状疱疹Shingrix创销售额纪录!疫苗业务已成为葛兰素史克业绩增长的核心驱动力,带疱疫苗销售...
After years of vaccine drought for respiratory syncytial virus (RSV), we are now on the brink of a deluge. GSK's vaccine candidate that protects older adults from RSV-related diseases received approval from the US Food and Drug Administration on May 3. The firm says it expects that the ...